MOUD Buprenorphine Subli denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for moud buprenorphine subli are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issued This Denial

Step therapy (also called "fail-first") requires a patient to try one or more alternative treatments before Aetna will cover the requested medication. For sublingual buprenorphine used as MOUD, a step-therapy denial often means Aetna wants evidence that another MOUD agent — or a prior treatment episode — was attempted first.

This denial category is especially vulnerable to appeal for two reasons. First, many states have enacted step-therapy override laws that require insurers to waive the step requirement when a clinician documents that an alternative would be contraindicated, clinically inferior, or previously tried unsuccessfully — check whether your state's law applies. Second, MHPAEA prohibits applying step-therapy requirements to substance use disorder treatments that are more onerous than requirements for analogous medical conditions.

## Why This Denial Is Appealable

Step-therapy denials are overturned when the chart shows the patient already failed, could not tolerate, or has a documented clinical reason to bypass the required prior step. You do not need to re-try a medication that previously caused harm or failed — you need documentation that this occurred.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the deadline in your denial letter. Aetna must respond within 30 days (standard) or 72 hours (expedited).
• External review (ACA §2719 / ERISA §503): Available after exhausting internal appeals, generally within four months of the final internal denial. An IRO can review whether Aetna's step-therapy requirement is consistent with its own criteria and clinical standards.
• State step-therapy override: If your state has a step-therapy protection law, your prescriber may be able to request an override directly — often with a faster timeline than a standard appeal.

## Concrete Appeal Steps

1. Obtain Aetna's step-therapy policy for buprenorphine MOUD — identify exactly which prior-step treatments Aetna requires. 2. Review the patient's treatment history to determine whether any required steps have already been tried (even informally or under prior coverage) — document dates, outcomes, and any adverse effects. 3. If required steps have not been tried, have the prescriber document a clinical reason why the step is contraindicated or clinically inappropriate for this patient. 4. Include a state step-therapy override request if your state law provides one. 5. Submit a MHPAEA parity argument if applicable. 6. Escalate to external review if the internal appeal fails.

## Documentation to Gather

• Aetna's step-therapy policy listing required prior-step medications
• Complete prior treatment history with dates, medications, doses (as documented in the chart), and outcomes
• Prescriber's letter explaining why the prior step is either already completed, contraindicated, or clinically inappropriate
• Chart notes corroborating the treatment history
• State step-therapy override form (if applicable)

## Criteria-Mapping Structure

| Aetna Step-Therapy Requirement | Chart Evidence | |---|---| | Prior-step medication tried | Treatment history with dates and outcomes | | Prior step failed / not tolerated / contraindicated | Chart notes documenting failure/intolerance or prescriber explanation | | Current request is medically necessary after prior steps | Prescriber medical-necessity letter |